NXN

NXN (nucleoredoxin) is a thioredoxin-family oxidoreductase that modulates multiple signaling pathways—including Wnt/β-catenin and NF-κB/AP-1/CREB—in a redox-dependent manner, linking cellular redox state to transcriptional and developmental programs (PMID:9119370, PMID:10903915). NXN possesses insulin-disulfide-reducing activity comparable to thioredoxin and localizes predominantly to the nucleus, where it differentially regulates transcription factor activation downstream of NIK, MEKK, and PKA signaling (PMID:9119370, PMID:10903915). Biallelic loss-of-function variants in NXN cause autosomal recessive Robinow syndrome through disruption of the WNT5A/noncanonical Wnt pathway required for skeletal development (PMID:29276006). NXN protein levels are themselves regulated by K63-linked ubiquitination mediated by the E3 ligase KCMF1, and NXN suppresses epithelial–mesenchymal transition by interacting with the deubiquitylase DUB3 to promote ubiquitin–proteasome degradation of Snail (PMID:35927236, PMID:41721648).

1. 1997 High

   Cloning and enzymatic characterization of NXN established it as a nuclear thioredoxin-family member with bona fide oxidoreductase activity, defining a new compartment-specific redox catalyst.

   Evidence Molecular cloning, in vitro insulin disulfide reduction assay, subcellular localization of tagged construct in transfected cells

   PMID:9119370

   Open questions at the time

   • Endogenous substrates in vivo were not identified
   • Whether nuclear localization is constitutive or regulated was not addressed
   • Catalytic mechanism and redox partners were not defined
2. 2000 Medium

   NXN was shown to differentially regulate NF-κB, AP-1, and CREB transcription factor activation, revealing that its nuclear oxidoreductase activity feeds into specific signaling outputs distinct from those of cytosolic thioredoxin or glutaredoxin.

   Evidence Luciferase reporter assays for NF-κB, AP-1, CREB in HEK293 cells co-expressing upstream kinases (NIK, MEKK, PKA)

   PMID:10903915

   Open questions at the time

   • Direct redox targets mediating transcription factor regulation were not identified
   • Only a single cell line was used
   • Endogenous NXN contribution versus overexpression artifacts not distinguished
3. 2007 Medium

   Placement of NXN as a redox-dependent regulator of the Wnt/β-catenin pathway consolidated its role beyond classical transcription factor modulation and linked it to cell growth and differentiation programs.

   Evidence Review synthesizing prior experimental data on Wnt/β-catenin regulation and domain/sequence analysis

   PMID:17567240

   Open questions at the time

   • Mechanistic basis of Wnt pathway regulation (direct binding partner, redox target) was not resolved
   • In vivo loss-of-function evidence was absent at this stage
4. 2017 Medium

   Human genetic evidence established NXN as a Robinow syndrome gene, demonstrating that its function within the WNT5A/noncanonical Wnt signaling pathway is essential for skeletal morphogenesis.

   Evidence Whole-exome sequencing of two families with biallelic NXN loss-of-function variants, co-segregation analysis, WNT5A interactome mapping

   PMID:29276006

   Open questions at the time

   • Functional rescue or animal model recapitulation was not reported in the same study
   • Whether NXN directly binds WNT5A pathway components or acts indirectly through redox sensing was unresolved
   • Genotype–phenotype spectrum across additional families was limited
5. 2022 Medium

   Discovery that NXN interacts with the deubiquitylase DUB3 and promotes Snail degradation via the ubiquitin–proteasome system revealed a non-redox effector mechanism by which NXN suppresses EMT and hepatocellular carcinoma metastasis.

   Evidence Reciprocal Co-IP, ubiquitination assays, gain/loss-of-function in vitro and in vivo xenograft models

   PMID:35927236

   Open questions at the time

   • Whether the NXN–DUB3 interaction depends on NXN redox state was not tested
   • Structural basis of the NXN–DUB3–Snail ternary complex is unknown
   • Generalizability beyond hepatocellular carcinoma not established
6. 2025 Medium

   Nxn-knockout mice exhibit pituitary dysmorphology and impaired Wnt-dependent differentiation of pituitary stem cells, providing the first in vivo loss-of-function model linking NXN to both canonical and noncanonical Wnt signaling in organogenesis.

   Evidence Mouse knockout, scRNAseq trajectory analysis, Wnt reporter assays (preprint)

   PMID:bio_10.1101_2025.01.30.635771

   Open questions at the time

   • Preprint not yet peer-reviewed
   • Molecular targets of NXN redox activity in pituitary progenitors remain unidentified
   • Whether skeletal phenotypes recapitulate human Robinow syndrome features was not fully characterized
7. 2026 Medium

   Identification of KCMF1 as an E3 ligase that degrades NXN via K63-linked ubiquitination established that NXN protein abundance is itself an actively regulated node controlling β-catenin pathway output.

   Evidence IP-LC/MS substrate identification, Co-IP, K63-linkage-specific ubiquitination assay, in vivo ovarian cancer xenograft models

   PMID:41721648

   Open questions at the time

   • Whether K63-ubiquitination also alters NXN subcellular localization or activity independently of degradation was not tested
   • Physiological contexts beyond ovarian cancer are unexplored
   • Interplay between KCMF1-mediated NXN degradation and NXN's own promotion of Snail degradation is unexplored

• The direct redox substrates through which NXN modulates Wnt and NF-κB signaling remain unidentified, and the structural basis for NXN's protein–protein interactions (DUB3, KCMF1) is unknown.
• No crystal or cryo-EM structure of NXN or its complexes exists
• Catalytic versus scaffolding contributions to Wnt pathway regulation have not been dissected
• Tissue-specific essentiality beyond skeletal and pituitary development is not mapped